Intermediate and High Risk Locally Regionally Advanced HNSCC

To evaluate the safety of the addition of nivolumab (anti PD-1 immunotherapy) to chemoradiotherapy with weekly cisplatin (40 mg/m2/week x 7) for patients with intermediate or high-risk head and neck squamous cell carcinoma.

August 09, 2017